Ginkgo Bioworks
DNA
DNA
260 hedge funds and large institutions have $1.93B invested in Ginkgo Bioworks in 2022 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 78 increasing their positions, 40 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
0.53% more ownership
Funds ownership: 1.27% → 1.8% (+0.53%)
28% less capital invested
Capital invested by funds: $2.68B → $1.93B (-$746M)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Holders
260
Holding in Top 10
8
Calls
$14.3M
Puts
$10.8M
Top Buyers
| 1 | +$137M | |
| 2 | +$89.4M | |
| 3 | +$70.3M | |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$52M |
| 5 |
BlackRock
New York
|
+$39M |
Top Sellers
| 1 | -$71.9M | |
| 2 | -$57.1M | |
| 3 | -$50.9M | |
| 4 |
HF
HRT Financial
New York
|
-$30.6M |
| 5 |
CC
Casdin Capital
New York
|
-$16.9M |